The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000838314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/06/2026
Date registered
Help: Date registered
10/07/2026
Date last updated
Help: Date last updated
10/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A study of the safety, tolerability and immune cell profile of one dose of Activated Immune Cells with Anti-Cancer Phenotype in healthy volunteers.
Scientific title
A study of the safety, tolerability and immune cell profile of one dose of Activated Immune Cells with Anti-Cancer Phenotype in healthy volunteers.
Additional trial identifiers [1] 317549 0
N/A
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cancer 342362 0
Condition category
Condition code
Cancer 338494 338494 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study will assess the safety, tolerability and immune cell profile of one dose of Activated Immune Cells with Anti-Cancer Phenotype in healthy volunteers.

Each healthy participant will receive a single intravenous infusion of Activated Immune Cells with Anti-Cancer Phenotype. Dose is dependent on harvested immune cells from participants and the dose administered will not be lower than 0.5 x 10^8 and not exceed 2 x 10^8.

The total maximum duration of the study will be 136 days (approximately 20 weeks). This includes a screening period of up to 29 days (Day -46 to Day -18), a 91-day treatment and follow-up period (Day -1 to Day 90), the dose will be given on Day 1 and the duration of the infusion will take approximately 30minutes.

PBMC harvest (Day -17)
The participant will report to the clinic 17 days prior to dosing for the collection of a blood sample (approximately 150ml) for the purpose of isolating PBMCs and preparing the Activated Immune Cells with Anti-Cancer Phenotype. They will be required to attend the clinic for approximately 1.5 to 2 hours to ensure that a sufficient blood volume has been collected, relevant tests completed and that they are able to leave safely.

Adherence will be completed via a schedule of assessments: Screening, PBMC harvest, Treatment period, Follow up (Self-monitoring Day 1, 2, 3, 4 & 14, Clinical outpatient visit - day 35, Phone call Day 63, End of Study Visit/Early Termination Visit - Day 90. Self-monitoring will occur at the participants' home.

Follow-ups and monitoring will be completed by clinical facility staff and includes, blood tests, vitals, ECG, Pharmacodynamics analysis, concomitant medication, physical examination.
Intervention code [1] 334343 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345727 0
To determine and evaluate the safety and tolerability of Activated Immune Cells with Anti-Cancer Phenotype administered as a single intravenous infusion in healthy participants. Safety and tolerability will be assessed as a composite primary outcome, incorporating the following measures: - Physical examination: A comprehensive physical examination will be conducted to assess any clinically significant changes from baseline in participant health status. - Adverse events (AEs): All adverse events, including serious adverse events (SAEs), will be recorded, graded by severity, and assessed for causality in accordance with CTCAE criteria throughout the study period. - Body weight: Participant body weight will be recorded to monitor for any clinically meaningful changes following administration. - Clinical laboratory assessments (pathology): Routine haematological and biochemical parameters measured. - Vital signs: Heart rate, blood pressure, body temperature, and respiratory rate. - 12-lead ECG: Cardiac safety assessment to identify any treatment-emergent changes in cardiac conduction or rhythm.
Timepoint [1] 345727 0
- Physical examination: Screening (once between Day -46 to -18), Pre-dose (Abbreviated - Day 1), and End Of Study (EOS - Day 90)/Early Terminal Visit (ETV). - Adverse events (AEs): PBMC Harvest (Day -17), Day 1 (pre-dose, dose and post-dose), Self-monitoring (Day 2, 3, 4 & 14), Clinic Outpatient Visit (Day 35), Phone call (Day 63) and EOS (Day 90)/ETV - Body weight: Screening (once between Day -46 to -18), pre-dose (Day 1), Clinic Outpatient Visit (Day 35), and EOS (Day 90)/ETV. - Clinical laboratory assessments (pathology): Screening (once between Day -46 to -18) and EOS (Day 90)/ETV. - Vital signs: Screening (once between Day -46 to -18), pre-dose and post-dose (Day 1), Self-assessed reporting (Day 2, 3, 4 & 14), Clinic Outpatient Visit (Day 35) and EOS/ETV. - 12-lead ECG: Screening (once between Day -46 to -18), Post-dose (Day 1), Clinic Outpatient Visit (Day 35) and EOS/ETV (Day 90). These tests may be repeated whenever a significant adverse event occurs.
Secondary outcome [1] 463080 0
Pharmacodynamic Assessment — The immune profile will be assessed as a composite secondary outcome through the collection of blood samples for the analysis of PBMC subpopulations and blood markers.
Timepoint [1] 463080 0
PBMC harvest (Day -17), Day 35 (clinic outpatient visit), Day 90 EOS/ETV.

Eligibility
Key inclusion criteria
1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects;

2. Adult males and females, 18 to 70 years of age (inclusive) at screening;

3. Body mass index greater than or equal to 18.0 and less than or equal to 30.0 kg/m2, with a body weight greater than or equal to 50 kg at screening;

4. Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 1 month prior to first study treatment administration;

5. Medically healthy without clinically significant abnormalities at screening and pre dose on Day 1, including:
a. Physical examination without any clinically relevant findings;
b. Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood pressure in the range of 50 to 95 mmHg after 5 minutes in supine position;
c. Heart rate ( HR) in the range of 50 to 100 bpm after 5 minutes rest in supine position;
d. Body temperature, between 35.0 °C and 37.5 °C;
e. No clinically significant findings in serum chemistry, haematology, coagulation and urinalysis tests as judged by the investigator;

6 . Conventional 12-lead electrocardiogram (ECG) recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at screening and pre dose on
Day 1) consistent with normal cardiac conduction and function, including:
a. Normal sinus rhythm with HR between 50 and 100 bpm, inclusive;
b. QT interval corrected using the Fridericia method ( QTcF) between 350 to 450 msec for male subjects and 350 to 470 msec for female subjects, inclusive;
c. QRS duration of less than 120 msec;
d. PR interval of less than or equal to 210 msec;
e. Electrocardiogram morphology consistent with healthy cardiac ventricular conduction and normal rhythm, and with measurement of the QT interval;
f. No family history of short or long QT syndrome;
g. No history of risk factors for torsade de pointes or the diagnosis;

7 . Female participants must:
a. Be of nonchildbearing potential ie, surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or postmenopausal ( where postmenopausal is defined as no menses for 12 months
without an alternative medical cause), or
b. If of childbearing potential, must have a negative pregnancy test at screening (blood test) and before the first study treatment administration (Day - 1 urine test). They must agree not to attempt to become pregnant, must not donate ova, and must use a highly effective contraceptive method from signing the consent form
until at least 30 days after the last dose of study treatment.

8 . Male participants, if not surgically sterilized, must be willing not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must bewilling to use a condom in addition to having the female partner use a highly effective contraceptive method from signing the consent form until at least 90 days after the last dose of study treatment;

9. Have suitable venous access for peripheral blood mononuclear cell (PBMC) collection and blood sampling;

10. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the
PI to be clinically relevant;

2. Current infection that requires antibiotic, antifungal, antiparasitic or antiviral medications;

3. Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma);

4. Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia;

5. Use of or plans to use systemic immunosuppressive (eg, corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (eg, interferon) during the
study or within 4 months prior to the first study treatment administration;

6. Liver function test results (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and total bilirubin must not be elevated more than 1.2-fold above the upper limit of normal (ULN);

7. Positive test results for active human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, human T-lymphotropic virus (HTLV)- 1/2 antibodies or syphilis;

8. Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs;

9. Estimated creatinine clearance (CrCl) < 40 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN;

10. History of substance abuse or alcohol abuse within 12 months prior to first study treatment administration;
11. Positive drug or alcohol test results;

12. Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study treatment administration, except occasional
use of paracetamol;

13. Demonstrated clinically significant (required intervention, eg, emergency room visit, epinephrine administration) allergic reactions (eg, food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the investigator, would interfere with the volunteer’s ability to participate in the trial;

14. Known hypersensitivity to any of the study treatment ingredients;

15. Use of any live vaccinations within 30 days prior to the first study treatment administration except for the influenza vaccine;

16. For women of childbearing potential, a positive serum pregnancy test at screening or a positive urine pregnancy test with confirmatory serum pregnancy test on Day - 1;

17. Donation of blood or plasma within 30 days prior to first study treatment administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study treatment administration;

18. Participation in another investigational clinical trial within 60 days prior to the first study treatment administration;

19. Any other condition or prior therapy that in the opinion of the PI would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study
requirements;

20. Is an employee of an investigator or sponsor or an immediate relative of an investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322107 0
Commercial sector/Industry
Name [1] 322107 0
Aeterna Health Services PTY LTD
Country [1] 322107 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Aeterna Health Services PTY LTD
Address
Country
Australia
Secondary sponsor category [1] 325011 0
None
Name [1] 325011 0
Address [1] 325011 0
Country [1] 325011 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320636 0
Bellberry Human Research Ethics Committee F
Ethics committee address [1] 320636 0
Ethics committee country [1] 320636 0
Australia
Date submitted for ethics approval [1] 320636 0
Approval date [1] 320636 0
21/05/2021
Ethics approval number [1] 320636 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151126 0
Dr Peter Lewis
Address 151126 0
Surecell - 1291 Malvern Road, Malvern, VIC, 3144
Country 151126 0
Australia
Phone 151126 0
+61 408352706
Fax 151126 0
Email 151126 0
Contact person for public queries
Name 151127 0
Peter Lewis
Address 151127 0
Surecell - 1291 Malvern Road, Malvern, VIC, 3144
Country 151127 0
Australia
Phone 151127 0
+61 408352706
Fax 151127 0
Email 151127 0
Contact person for scientific queries
Name 151128 0
Peter Lewis
Address 151128 0
Surecell - 1291 Malvern Road, Malvern, VIC, 3144
Country 151128 0
Australia
Phone 151128 0
+61 408352706
Fax 151128 0
Email 151128 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.